Lavendustin A

• UNSPSC Description:

  Lavendustin A (RG-14355) is a potent, selective and ATP-competitive inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, with an IC50 of 11 nM. Lavendustin A does not inhibit protein kinase A or C. Lavendustin A can suppress VEGF-induced angiogenesis[1][2].

• Target Antigen:

  EGFR

• Type:

  Natural Products

• Related Pathways:

  JAK/STAT Signaling;Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Lavendustin_A.html

• Purity:

  98.02

• Solubility:

  DMSO : 25 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  O=C(O)C1=CC(N(CC2=CC(O)=CC=C2O)CC3=CC=CC=C3O)=CC=C1O

• Molecular Weight:

  381.38

• References & Citations:

  [1]Onoda T, et, al. Isolation of a novel tyrosine kinase inhibitor, lavendustin A, from Streptomyces griseolavendus. J Nat Prod. 1989 Nov-Dec;52(6):1252-7. |[2]Hu DE, et, al. Suppression of VEGF-induced angiogenesis by the protein tyrosine kinase inhibitor, lavendustin A. Br J Pharmacol. 1995 Jan;114(2):262-8. |[3]Whitehead SA, et, al. Protein tyrosine kinase activity of lavendustin A and the phytoestrogen genistein on progesterone synthesis in cultured rat ovarian cells. Fertil Steril. 2000 Mar;73(3):613-9.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, stored under nitrogen)

• Clinical Information:

  No Development Reported

• CAS Number:

  125697-92-9